CompanyXFORNasdaqBoston, MA

X4 Pharmaceuticals

X4 Pharmaceuticals develops mavorixafor, an oral CXCR4 antagonist approved for WHIM syndrome and in Phase 3 trials for chronic neutropenic disorders.

SEC EDGAR ClinicalTrials.gov x4pharma.com

SCHEDULE 13GSep 21Latest SEC filing

Sep 8Latest story

September 2026

X4 Pharmaceuticals gets FDA agreement to cut 4WARD trial size to 126 patients

Sep 8Clinical readoutX4 Pharmaceuticals

July 2026

X4 Pharmaceuticals adds CAMP4 Therapeutics CFO Kelly Gold to its board

Jul 1PeopleX4 Pharmaceuticals